Literature DB >> 23139018

A pharmacokinetic simulation tool for inhaled corticosteroids.

Benjamin Weber1, Guenther Hochhaus.   

Abstract

The pharmacokinetic (PK) behavior of inhaled drugs is more complicated than that of other forms of administration. In particular, the effects of certain physiological (mucociliary clearance and differences in membrane properties in central and peripheral (C/P) areas of the lung), formulation (as it relates to drug deposition and particle dissolution rate), and patient-related factors (lung function; effects on C/P deposition ratio) affect the systemic PKs of inhaled drugs. The objectives of this project were (1) to describe a compartmental model that adequately describes the fate of inhaled corticosteroids (ICS) after administration while incorporating variability between and within subjects and (2) based upon the model, to provide a freely available tool for simulation of PK trials after ICS administration. This compartment model allows for mucociliary removal of undissolved particles from the lung, distinguishes between central and peripheral regions of the lung, and models drug entering the systemic circulation via the lung and the gastrointestinal tract. The PK simulation tool is provided as an extension package to the statistical software R ('ICSpkTS'). It allows simulation of PK trials for hypothetical ICS and of four commercially available ICS (budesonide, flunisolide, fluticasone propionate, and triamcinolone acetonide) in a parallel study design. Simulated PK data and parameters agreed well with literature data for all four ICS. The ICSpkTS package is especially suitable to explore the effect of changes in model parameters on PK behavior and can be easily adjusted for other inhaled drugs.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23139018      PMCID: PMC3535116          DOI: 10.1208/s12248-012-9420-z

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  43 in total

Review 1.  Simulation of clinical trials.

Authors:  N H Holford; H C Kimko; J P Monteleone; C C Peck
Journal:  Annu Rev Pharmacol Toxicol       Date:  2000       Impact factor: 13.820

2.  Single-dose and steady-state pharmacokinetic and pharmacodynamic evaluation of therapeutically clinically equivalent doses of inhaled fluticasone propionate and budesonide, given as Diskus or Turbohaler dry-powder inhalers to healthy subjects.

Authors:  H Möllmann; M Wagner; S Krishnaswami; H Dimova; Y Tang; C Falcoz; P T Daley-Yates; M Krieg; R Stöckmann; J Barth; C Lawlor; A C Möllmann; H Derendorf; G Hochhaus
Journal:  J Clin Pharmacol       Date:  2001-12       Impact factor: 3.126

3.  Mucociliary clearance in adult asthma.

Authors:  T G O'Riordan; J Zwang; G C Smaldone
Journal:  Am Rev Respir Dis       Date:  1992-09

4.  Inhaled corticosteroids in asthma: a dose-proportionality study with triamcinolone acetonide aerosol.

Authors:  B A Zaborny; P Lukacsko; I Barinov-Colligon; J A Ziemniak
Journal:  J Clin Pharmacol       Date:  1992-05       Impact factor: 3.126

Review 5.  Do airway clearance mechanisms influence the local and systemic effects of inhaled corticosteroids?

Authors:  Staffan Edsbäcker; Per Wollmer; Olof Selroos; Lars Borgström; Bo Olsson; Jarl Ingelf
Journal:  Pulm Pharmacol Ther       Date:  2007-09-06       Impact factor: 3.410

6.  Lung deposition of budesonide from turbuhaler in asthmatic children.

Authors:  J H Wildhaber; S G Devadason; J M Wilson; C Roller; T Lagana; L Borgström; P N LeSouëf
Journal:  Eur J Pediatr       Date:  1998-12       Impact factor: 3.183

7.  Absorption of aerosolized drugs from the rat lung.

Authors:  R A Brown; L S Schanker
Journal:  Drug Metab Dispos       Date:  1983 Jul-Aug       Impact factor: 3.922

Review 8.  In vivo-in vitro correlations: predicting pulmonary drug deposition from pharmaceutical aerosols.

Authors:  Peter R Byron; Michael Hindle; Carlos F Lange; P Worth Longest; Donald McRobbie; Michael J Oldham; Bo Olsson; Charles G Thiel; Herbert Wachtel; Warren H Finlay
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2010-12       Impact factor: 2.849

9.  Pulmonary distribution and kinetics of inhaled [11C]triamcinolone acetonide.

Authors:  M S Berridge; Z Lee; D L Heald
Journal:  J Nucl Med       Date:  2000-10       Impact factor: 10.057

10.  Budesonide and ciclesonide: effect of tissue binding on pulmonary receptor binding.

Authors:  Kai Wu; Anders L Blomgren; Kjell Ekholm; Benjamin Weber; Staffan Edsbaecker; Günther Hochhaus
Journal:  Drug Metab Dispos       Date:  2009-04-13       Impact factor: 3.922

View more
  17 in total

1.  A Systematic Analysis of the Sensitivity of Plasma Pharmacokinetics to Detect Differences in the Pulmonary Performance of Inhaled Fluticasone Propionate Products Using a Model-Based Simulation Approach.

Authors:  Benjamin Weber; Guenther Hochhaus
Journal:  AAPS J       Date:  2015-05-02       Impact factor: 4.009

2.  Hair cortisol as a novel biomarker of HPA suppression by inhaled corticosteroids in children.

Authors:  Laura Smy; Kaitlyn Shaw; Anne Smith; Evan Russell; Stan Van Uum; Michael Rieder; Bruce Carleton; Gideon Koren
Journal:  Pediatr Res       Date:  2015-03-19       Impact factor: 3.756

Review 3.  Pharmacometric Models for Characterizing the Pharmacokinetics of Orally Inhaled Drugs.

Authors:  Jens Markus Borghardt; Benjamin Weber; Alexander Staab; Charlotte Kloft
Journal:  AAPS J       Date:  2015-04-07       Impact factor: 4.009

4.  Predicting Pulmonary Pharmacokinetics from In Vitro Properties of Dry Powder Inhalers.

Authors:  Sharvari Bhagwat; Uta Schilling; Mong-Jen Chen; Xiangyin Wei; Renishkumar Delvadia; Mohammad Absar; Bhawana Saluja; Günther Hochhaus
Journal:  Pharm Res       Date:  2017-08-10       Impact factor: 4.200

Review 5.  Inhaled Antibiotics for Gram-Negative Respiratory Infections.

Authors:  Eric Wenzler; Dustin R Fraidenburg; Tonya Scardina; Larry H Danziger
Journal:  Clin Microbiol Rev       Date:  2016-07       Impact factor: 26.132

6.  Linking Suspension Nasal Spray Drug Deposition Patterns to Pharmacokinetic Profiles: A Proof-of-Concept Study Using Computational Fluid Dynamics.

Authors:  Alex Rygg; Michael Hindle; P Worth Longest
Journal:  J Pharm Sci       Date:  2016-06       Impact factor: 3.534

7.  In Vitro, Pharmacokinetic, Pharmacodynamic, and Safety Comparisons of Single and Combined Administration of Tiotropium and Salmeterol in COPD Patients Using Different Dry Powder Inhalers.

Authors:  Stephen T Horhota; Jan A van Noord; Cynthia B Verkleij; Loek J Bour; Ashish Sharma; Michael Trunk; Piet J G Cornelissen
Journal:  AAPS J       Date:  2015-03-21       Impact factor: 4.009

Review 8.  Assessment of the predictive capability of modelling and simulation to determine bioequivalence of inhaled drugs: A systematic review.

Authors:  Juliet Rebello; Bill Brashier; Sharvari Shukla
Journal:  Daru       Date:  2022-01-30       Impact factor: 4.088

9.  A Systematic Approach in the Development of the Morphologically-Directed Raman Spectroscopy Methodology for Characterizing Nasal Suspension Drug Products.

Authors:  Gonçalo Farias; Jagdeep Shur; Robert Price; Elizabeth Bielski; Bryan Newman
Journal:  AAPS J       Date:  2021-05-18       Impact factor: 4.009

Review 10.  Inhalation monoclonal antibody therapy: a new way to treat and manage respiratory infections.

Authors:  Hilal Ahmad Parray; Shivangi Shukla; Reshma Perween; Ritika Khatri; Tripti Shrivastava; Vanshika Singh; Praveenkumar Murugavelu; Shubbir Ahmed; Sweety Samal; Chandresh Sharma; Subrata Sinha; Kalpana Luthra; Rajesh Kumar
Journal:  Appl Microbiol Biotechnol       Date:  2021-08-23       Impact factor: 5.560

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.